Drug intelligence / Profile preview

NBL-021

Development stage: Preclinical
Lead developer: NovaRock Biotherapeutics
Modality: Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

NBL-021 is a multispecific engager (MuSE) targeting Programmed Death-Ligand 1 (PD-L1), developed by NovaRock Biotherapeutics. Utilizing the proprietary MuSE platform, NBL-021 is designed to enhance the therapeutic efficacy of PD-L1 inhibition in the treatment of solid tumors and hematologic malignancies. The MuSE architecture typically involves multispecific antibody formats intended to optimize immune cell engagement or tumor targeting. As of 2021, the program was in the IND-enabling phase of development.

Targets

CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on NBL-021.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NBL-021.

Explore the full profile